Effect of Method of Regulating Qi to Dissipate Blood Stasis and Phlegm on Blood Lipid Metabolism of Patients with Chronic Heart Failure and Dyslipidemia

LI Pei-pei; LIU Ting; MA Hong-bo

doi:10.13422/j.cnki.syfjx.20182145

您当前的位置：

首页 >

文章列表页 >

Effect of Method of Regulating Qi to Dissipate Blood Stasis and Phlegm on Blood Lipid Metabolism of Patients with Chronic Heart Failure and Dyslipidemia

更新时间：2024-09-23

- Effect of Method of Regulating Qi to Dissipate Blood Stasis and Phlegm on Blood Lipid Metabolism of Patients with Chronic Heart Failure and Dyslipidemia
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 21, Pages: 199-204(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20182145
  CLC： R259
- Published：2018
- 稿件说明：
移动端阅览
LI Pei-pei, LIU Ting, MA Hong-bo. Effect of Method of Regulating Qi to Dissipate Blood Stasis and Phlegm on Blood Lipid Metabolism of Patients with Chronic Heart Failure and Dyslipidemia[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(21): 199-204.
DOI：

LI Pei-pei, LIU Ting, MA Hong-bo. Effect of Method of Regulating Qi to Dissipate Blood Stasis and Phlegm on Blood Lipid Metabolism of Patients with Chronic Heart Failure and Dyslipidemia[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(21): 199-204. DOI： 10.13422/j.cnki.syfjx.20182145.

摘要

目的：观察理气化痰祛瘀法对慢性心力衰竭（CHF）伴血脂异常血脂代谢的影响及调节血管内皮功能、炎症因子和氧化应激的作用。方法：将118例符合要求的患者，按随机数字表法分为对照组和观察组各58例。两组患者基础治疗均口服螺内酯片，20 mg/次，1次/d；盐酸贝那普利片，20 mg/次，1次/d；富马酸比索洛尔片，10 mg/次，1次/d。对照组加服阿托伐他汀钙片，10 mg/次，1次/d；观察组西药治疗同对照组，加用丹参饮合血府逐瘀汤加减，1剂/d。两组疗程均连续治疗2个月。检测治疗前后总胆固醇（TC），甘油三酯（TG），低密度脂蛋白胆固醇（LDL-C），高密度脂蛋白胆固醇（HDL-C），脂蛋白（a）（Lp-a）水平；检测治疗前后一氧化氮（NO），内皮素-1（ET-1）和血清血管性假血友病因子（vWF），脂联素（APN），瘦素（LP），白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α），超氧化物歧化酶（SOD）和丙二醛（MDA）水平；进行治疗前后超声心动图检查，记录左心室收缩期内径（LVIDd），左室射血分数（EF），每搏输出量（SV），心输出量（CO）和二尖瓣口舒张早期及舒张晚期流速峰值（E/A）。结果：经Ridit分析，观察组中医证候疗效优于对照组（P<0.05）；观察组HDL-C水平高于对照组，LDL-C水平低于对照组（P<0.05），观察组患者Lp-a水平低于对照组（P<0.05），观察组LDL-C和HDL-C异常例数均少于对照组（P<0.05）；观察组ET-1，vWF，MDA均低于对照组，NO和SOD水平均高于对照组（P<0.01）；观察组血清IL-6，TNF-α和LP水平均低于对照组，APN水平高于对照组（P<0.01）；治疗后观察组LVEF，SV，CO和E/A均高于对照组（P<0.05）。结论：理气化痰祛瘀法治疗CHF伴血脂异常患者，可调节患者脂代谢，改善心功能症状，具有调节血管内皮功能及抗炎、抗氧化的功能，从而起到改善CHF预后的作用。

Abstract

Objective: To observe the effect of method of regulating Qi to dissipate blood stasis and phlegm on blood lipid metabolism of patients with chronic heart failure (CHF) and dyslipidemia and investigate its effect on regulating vascular endothelial function

inflammatory factors and oxidative stress. Method: One hundred and eighteen eligible patients were randomly divided into control group (58 cases) and observation group (58 cases) by random number table. Both groups received spironolactone tablets

20 mg/time

qd. Benazepril hydrochloride tablets

20 mg/time

qd. Bisoprolol tumarate tablets

10 mg/time

qd. Patients in control group got atorvastatin

10 mg/time

qd. Based on the treatment in control group

patients in observation group additionally received add and subtract Danshen Tang and Xuefu Zhuyu Tang

1 dose/day. The treatment course was 2 months for both groups. Before and after treatment

levels of total cholesterol (TC)

triglyceride (TG)

low density lipoprotein (LDL-C)

high density lipoprotein water (HDL-C)

lipoprotein (a) (Lp-a)

nitric oxide (NO)

endothelin-1 (ET-1)

von Willebrand factor (vWF)

adiponectin (APN)

leptin (LP)

interleukins-6 (IL-6)

tumor necrosis factor-α (TNF-α)

superoxide dismutase (SOD) and malondialdehyde (MDA) were detected. Echocardiography

left ventricular end diastolic diameter (LVIDd)

left ventricular ejection fraction (EF)

stroke volume (SV)

cardiac output (CO) and the ratio of the peak velocity of early stage and advanced stage of diastolic phase at the mitral orifice (E/A) were recorded before and after treatment. Result: Ridit analysis showed that the clinical efficacy for traditional Chinese medicine syndrome in observation group was better than that in control group (P<0.05). Level of HDL-C in observation group was higher than that in control group

and level of LDL-C was lower than that in control group (P<0.05). Level of Lp-a was lower than that in control group (P<0.05)

and the number of abnormal cases for LDL-C and HDL-C were less than those in control group (P<0.05). Levels of ET-1

vWF

MDA

IL-6

TNF-α and LP in observation group were lower than those in control group (P<0.01)

while levels of NO

SOD

APN

LVEF

CO and E/A were higher than those in control group (P<0.05

P<0.01). Conclusion: In the treatment of CHF and dyslipidemia with method of regulating Qi to dissipate blood stasis and phlegm can regulate lipid metabolism and vascular endothelial function

ameliorate cardiac function and symptoms

with anti-inflammatory and antioxidation effects to improve prognosis of CHF.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Protective Effect of Shengxiantang on Myocardial Microvascular Injury in Rats with Chronic Heart Failure

Effect of Yiqi Wenyang Huoxue Lishui Components on Cardiac Function and Mitochondrial Energy Metabolism in CHF Rats

Effect of Linggui Zhugantang on Mitochondrial Fusion-fission and Sirt3/ AMPK Signaling Pathway in Chronic Heart Failure Rats After Myocardial Infarction

Metabonomic Analysis of Wenfei Huaxian Granules Against Idiopathic Pulmonary Fibrosis in Mice

Effect of Shenling Guchang Prescription on Gestational Diabetes Rats Based on Intestinal Microecology

Related Author

GAO Hui

YANG Zeqi

GAO Fan

LI Hongjing

LU Aiyangzi

LIU Xingchao

GUO Qiuhong

GAO Hui

Related Institution

Hebei University of Chinese Medicine

Hebei Provincial Hospital of Traditional Chinese Medicine（TCM）

Hebei Technology Innovation Center for TCM Formula Preparations

Hebei Higher Education Institute Applied Technology Research Center for TCM Development and Industrialization

Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰